Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13227
Peer-review started: July 7, 2022
First decision: October 27, 2022
Revised: November 7, 2022
Accepted: December 5, 2022
Article in press: December 5, 2022
Published online: December 26, 2022
Processing time: 172 Days and 6.1 Hours
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of mediastinal and hilar lymph is poorly studied in patients with extrathoracic malignancies.
To evaluate the value of EBUS-TBNA for the diagnosis of enlarged intrathoracic lymph nodes in patients with extrathoracic malignancies.
This was a retrospective study of patients with extrathoracic malignancies who were referred to Peking University Cancer Hospital from January 2013 to December 2018 for EBUS-TBNA due to intrathoracic lymphadenopathy. The specimens were defined as positive for malignancy, negative for non-malignancy (tuberculosis, sarcoidosis, etc.), and without a definitive diagnosis. Sensitivity, negative predictive value (NPV) for malignancy, and overall accuracy were calculated. Complications were recorded.
A total of 80 patients underwent EBUS-TBNA and had a final diagnosis, among which 50 (62.5%) were diagnosed with extrathoracic malignancy with intr
EBUS-TBNA is a simple and accurate procedure for the diagnosis of intrathoracic lymphadenopathy with extrathoracic malignancy.
Core Tip: This was a retrospective study of patients referred to Peking University Cancer Hospital from January 2013 to December 2018 for endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) due to intrathoracic lymphadenopathy. The specimens were defined as positive for malignancy, negative for non-malignancy (tuberculosis, sarcoidosis, etc.), and without definite diagnosis. Sensitivity, negative predictive value for malignancy, and overall accuracy were calculated. EBUS-TBNA was found to be a simple and accurate procedure for the diagnosis of intrathoracic lymphadenopathy with extrathoracic malignancy.